ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Ardelyx CFO sells $6,009 in shares via tax-withholding transaction

Susan Hohenleitner disposed of 1,558 Ardelyx shares on August 21 to cover tax obligations on vested restricted stock units. The sale occurred as the biopharma stock trades near a 52-week low.

PA
Priya Anand · Equities & Earnings Desk · 31 Aug 2026 · 04:06 · 1 min read
Share
Ardelyx CFO sells $6,009 in shares via tax-withholding transaction

Chief Financial Officer Susan Hohenleitner of Ardelyx Inc. sold 1,558 shares of common stock on August 21 to satisfy U.S. tax withholding requirements tied to the vesting of restricted stock units. The transaction, executed as a "sell-to-cover" order, generated approximately $6,009 in proceeds at a weighted average price of $3.8569 per share, with individual trades ranging from $3.648 to $3.984.

The disposal leaves Hohenleitner with a direct holding of 227,520 Ardelyx shares. The filing was signed on August 25 and reported to regulators under standard insider-transaction protocols.

Ardelyx’s stock has declined 35% year-to-date and is trading near its 52-week low of $3.73, down from a 2026 peak of $8.40. The company’s market capitalization stands at $932 million, and its shares are cited as undervalued relative to InvestingPro’s Fair Value estimate.

The CFO’s transaction follows recent corporate developments. Second-quarter revenue rose 31% year-over-year to a record $118 million, though the company adjusted full-year guidance for IBSRELA and withdrew its revenue target for XPHOZAH, contributing to after-hours share weakness. Options activity surged to 11,147 contracts, the highest since April 2025, with put volume totaling 10,676 contracts compared to 471 calls.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT